Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Demecolcine results in decreased expression of MTHFD2L mRNA | CTD | PMID:23649840 | 17beta-estradiol | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of MTHFD2L mRNA | CTD | PMID:30165855 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MTHFD2L mRNA | CTD | PMID:32741896 | 17beta-estradiol 3-benzoate | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MTHFD2L mRNA | CTD | PMID:32741896 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin affects the expression of MTHFD2L mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MTHFD2L mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of MTHFD2L mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of MTHFD2L mRNA | CTD | PMID:20106945 and PMID:21632981 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of MTHFD2L mRNA | CTD | PMID:24780913 | acrylamide | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Acrylamide results in increased expression of MTHFD2L mRNA | CTD | PMID:32763439 | aflatoxin B1 | affects expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Aflatoxin B1 affects the expression of MTHFD2L protein | CTD | PMID:20106945 | aflatoxin B1 | decreases methylation | ISO | MTHFD2L (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of MTHFD2L gene | CTD | PMID:27153756 | aflatoxin B1 | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of MTHFD2L mRNA | CTD | PMID:21632981 | aristolochic acid A | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of MTHFD2L mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to MTHFD2L mRNA] | CTD | PMID:32406909 | atrazine | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Atrazine results in decreased expression of MTHFD2L mRNA | CTD | PMID:22378314 | benzo[a]pyrene | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of MTHFD2L mRNA | CTD | PMID:20106945 and PMID:21632981 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of MTHFD2L mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of MTHFD2L mRNA | CTD | PMID:33670352 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of MTHFD2L mRNA | CTD | PMID:30816183 and PMID:32528016 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of MTHFD2L gene | CTD | PMID:28505145 | butanal | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of MTHFD2L mRNA | CTD | PMID:26079696 | cadmium atom | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Cadmium results in increased expression of MTHFD2L mRNA | CTD | PMID:21120746 | cadmium dichloride | increases methylation | EXP | | 6480464 | Cadmium Chloride results in increased methylation of MTHFD2L promoter | CTD | PMID:22457795 | caffeine | decreases expression | EXP | | 6480464 | Caffeine results in decreased expression of MTHFD2L mRNA | CTD | PMID:20864626 | CGP 52608 | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to MTHFD2L gene] | CTD | PMID:28238834 | cobalt dichloride | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | cobaltous chloride results in increased expression of MTHFD2L mRNA | CTD | PMID:19376846 | copper atom | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MTHFD2L mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MTHFD2L mRNA | CTD | PMID:20971185 | cyclosporin A | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of MTHFD2L mRNA | CTD | PMID:20106945 more ... | diclofenac | increases expression | EXP | | 6480464 | Diclofenac results in increased expression of MTHFD2L mRNA | CTD | PMID:30723492 | dorsomorphin | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of MTHFD2L mRNA | CTD | PMID:29803840 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of MTHFD2L mRNA | CTD | PMID:29391264 | ethyl methanesulfonate | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of MTHFD2L mRNA | CTD | PMID:23649840 | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of MTHFD2L mRNA | CTD | PMID:30307764 | formaldehyde | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of MTHFD2L mRNA | CTD | PMID:23649840 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of MTHFD2L mRNA | CTD | PMID:33387578 | manganese(II) chloride | increases expression | EXP | | 6480464 | manganese chloride results in increased expression of MTHFD2L mRNA | CTD | PMID:28801915 | methapyrilene | increases expression | EXP | | 6480464 | Methapyrilene results in increased expression of MTHFD2L mRNA | CTD | PMID:30467583 | methoxyacetic acid | decreases expression | EXP | | 6480464 | methoxyacetic acid results in decreased expression of MTHFD2L mRNA | CTD | PMID:20864626 | methyl methanesulfonate | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of MTHFD2L mRNA | CTD | PMID:23649840 | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of MTHFD2L mRNA | CTD | PMID:20864626 | methylmercury chloride | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of MTHFD2L mRNA | CTD | PMID:28001369 | Monobutylphthalate | decreases expression | EXP | | 6480464 | monobutyl phthalate results in decreased expression of MTHFD2L mRNA | CTD | PMID:20864626 | N-methyl-4-phenylpyridinium | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of MTHFD2L mRNA | CTD | PMID:24810058 | panobinostat | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | panobinostat | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | panobinostat results in increased expression of MTHFD2L mRNA | CTD | PMID:26272509 | paracetamol | affects expression | ISO | Mthfd2l (Mus musculus) | 6480464 | Acetaminophen affects the expression of MTHFD2L mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of MTHFD2L mRNA | CTD | PMID:33387578 | pentanal | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | pentanal results in decreased expression of MTHFD2L mRNA | CTD | PMID:26079696 | phenylmercury acetate | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of MTHFD2L mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | Mthfd2l (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of MTHFD2L mRNA | CTD | PMID:20813756 | pirinixic acid | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of MTHFD2L mRNA | CTD | PMID:19710929 | potassium dichromate | decreases expression | ISO | Mthfd2l (Mus musculus) | 6480464 | Potassium Dichromate results in decreased expression of MTHFD2L mRNA | CTD | PMID:23608068 | quercetin | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Quercetin results in decreased expression of MTHFD2L mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | increases expression | ISO | Mthfd2l (Mus musculus) | 6480464 | sodium arsenite results in increased expression of MTHFD2L mRNA | CTD | PMID:37682722 | temozolomide | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Temozolomide results in decreased expression of MTHFD2L mRNA | CTD | PMID:31758290 | testosterone | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MTHFD2L mRNA | CTD | PMID:32741896 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of MTHFD2L mRNA | CTD | PMID:31150632 | thimerosal | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Thimerosal results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of MTHFD2L mRNA | CTD | PMID:34492290 | titanium dioxide | decreases expression | ISO | Mthfd2l (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of MTHFD2L mRNA | CTD | PMID:29264374 | trichostatin A | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | trichostatin A results in increased expression of MTHFD2L mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | trimellitic anhydride | decreases expression | ISO | Mthfd2l (Mus musculus) | 6480464 | trimellitic anhydride results in decreased expression of MTHFD2L mRNA | CTD | PMID:19042947 | valproic acid | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of MTHFD2L mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of MTHFD2L mRNA | CTD | PMID:24383497 and PMID:27188386 | valproic acid | decreases methylation | ISO | MTHFD2L (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of MTHFD2L gene | CTD | PMID:29154799 | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of MTHFD2L mRNA | CTD | PMID:23869203 | vincristine | decreases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | Vincristine results in decreased expression of MTHFD2L mRNA | CTD | PMID:23649840 | vorinostat | multiple interactions | ISO | MTHFD2L (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | vorinostat | increases expression | ISO | MTHFD2L (Homo sapiens) | 6480464 | vorinostat results in increased expression of MTHFD2L mRNA | CTD | PMID:27188386 | |